Advertisement

The benefit of liver transplant beyond Milan criteria: An analysis using the National Cancer Database

Published:September 09, 2022DOI:https://doi.org/10.1016/j.surg.2022.07.020

      Abstract

      Background

      Published studies examining the efficacy of liver transplantation in patients presenting with hepatocellular cancer beyond the traditional Milan criteria for liver transplantation have primarily been single institution series with limited ability to compare outcomes to alternative methods of management.

      Methods

      We queried the National Cancer Database to identify patients presenting between 2004 and 2016 with histologically confirmed clinical stage III and IVA hepatocellular cancer. Multivariable regression was used to identify factors associated with liver transplantation. Patients undergoing liver transplantation were 1:1 propensity score-matched for age, demographics, comorbid disease, clinical stage, and histologic resection margin to those undergoing surgical resection. The Kaplan-Meier method was used to compare overall survival profiles for matched cohorts.

      Results

      Seven hundred and ninety-two patients met inclusion criteria—590 (74.5%) underwent surgical resection and 202 (25.5%) liver transplantation. On adjusted analysis, patients undergoing liver transplantation were less likely to have advanced age (>60 years; odds ratio 0.39, 95% confidence interval [0.21–0.71]) and to be of Black race (odds ratio 0.42, 95% confidence interval [0.23–0.73]) or Asian (odds ratio 0.25, 95% confidence interval [0.11–0.53]) ethnicity but were more likely to have advanced (Charlson score >2) comorbidity scores, (odds ratio 2.48, 95% confidence interval [1.58–3.90]) and more likely to have private health insurance (odds ratio 4.17, 95% confidence interval [1.31–18.66]) than those undergoing surgical resection. On Kaplan-Meier analysis of matched cohorts, patients undergoing liver transplantation demonstrated significantly better rates of 5-year overall survival (65.3% vs 26.3%, P < .0001) and longer median overall survival times than those undergoing resection (53.1 ± 2.78 vs 26.9 ± 1.20 months, P < .0001).

      Conclusion

      Liver transplantation offers the potential to be an effective treatment modality in select patients presenting with stage III and IVA hepatocellular cancer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2020. https://gco.iarc.fr/today. Accessed December 2021.

        • Wedd J.P.
        • Nordstrom E.
        • Nydam T.
        • et al.
        Hepatocellular carcinoma in patients listed for liver transplantation: current and future allocation policy and management strategies for the individual patient.
        Liver Transpl. 2015; 21: 1543-1552
        • Vibert E.
        • Schwartz M.
        • Olthoff K.M.
        Advances in resection and transplantation for hepatocellular carcinoma.
        J Hepatol. 2020; 72: 262-276
        • Akoad M.E.
        • Pomfret E.A.
        Surgical resection and liver transplantation for hepatocellular carcinoma.
        Clin Liver Dis. 2015; 19: 381-399
        • Mazzaferro V.
        • Regalia E.
        • Doci R.
        • et al.
        Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.
        N Engl J Med. 1996; 334: 693-700
        • Clavien P.A.
        • Lesurtel M.
        • Bossuyt P.M.
        • Gores G.J.
        • Langer B.
        • Perrier A.
        Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.
        Lance Oncol. 2012; 13: e11-e22
        • Jonas S.
        • Bechstein W.O.
        • Steinmuller T.
        • et al.
        Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.
        Hepatology. 2001; 5: 1080-1086
        • Bruix J.
        • Fuster J.
        • Llovet J.M.
        Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision.
        Liver Transpl. 2003; 7: 700-702
        • Yao F.
        Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.
        Hepatology. 2001; 33: 1394-1403
        • Herrero J.I.
        • Sangro B.
        • Pardo F.
        • et al.
        Liver transplantation in patients with hepatocellular carcinoma across Milan criteria.
        Liver Transpl. 2008; 14: 272-278
        • Mazzaferro V.
        • Chun Y.S.
        • Poon R.
        • et al.
        Liver transplantation for hepatocellular carcinoma.
        Ann Surg Oncol. 2008; 15: 1001-1007
        • Polat K.Y.
        • Acar S.
        • Gencdal G.
        • et al.
        Hepatocellular carcinoma and liver transplantation: a single-center experience.
        Transplant Proc. 2020; 52: 259-264
      2. European Liver Transplant Registry.
        (Results; 2021)
        http://www.eltr.org/-Results-.html
        Date accessed: February 27, 2021
        • Silva M.
        • Moya A.
        • Berenguer M.
        • et al.
        Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma.
        Liver Transpl. 2008; 14: 1449-1460
        • Finotti M.
        • Vitale A.
        • Volk M.
        • Cillo U.
        A 2020 update on liver transplant for hepatocellular carcinoma.
        Expert Rev Gastroenterol Hepatol. 2020; 14: 885-900
        • Cillo U.
        • Vitale A.
        • Bassanello M.
        • et al.
        Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma.
        Ann Surg. 2004; 239: 150-159
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • et al.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Roayaie S.
        • Frischer J.S.
        • Emre S.H.
        • et al.
        Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters.
        Ann Surg. 2002; 235: 533-539
        • Xu X.
        • Lu D.
        • Ling Q.
        • et al.
        Liver transplantation for hepatocellular carcinoma beyond the Milan criteria.
        Gut. 2015; 65: 1035-1041
        • Rahatli S.
        • Ayvazoglu Soy E.H.
        • Oguz A.
        • Altundag O.
        • Moray G.
        • Haberal M.
        Single-center experience of recurrence patterns and survival analyses of patients with hepatocellular carcinoma and liver transplant.
        Exp Clin Transplant. 2020; 18: 201-205
        • Heimbach J.K.
        Evolution of liver transplant selection criteria and U.S. allocation policy for patients with hepatocellular carcinoma.
        Semin Liver Dis. 2020; 40: 358-364
        • Mehta N.
        • Bhangui P.
        • Yao F.Y.
        • et al.
        Liver transplantation for hepatocellular carcinoma. working group report from the ILTS Transplant Oncology Consensus Conference.
        Transplantation. 2020; 104: 1136-1142
        • Monlezun D.J.
        • Darden M.
        • Friedlander P.
        • Balart L.
        • Parker G.
        • Buell J.F.
        Racial and regional disparity in liver transplant allocation.
        Surgery. 2018; 163: 612-616